Filtros de búsqueda

Lista de obras de Nadia Harbeck

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

artículo científico publicado en 2013

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts

artículo científico publicado en 2015

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

artículo científico publicado en 2007

A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology

artículo científico publicado en 2016

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer ⬇️

artículo científico publicado el 5 de julio de 2012

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

artículo científico publicado en 2016

A randomized, window of opportunity study comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ HER2- primary breast cancer

scientific article published on 31 March 2020

ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011.

artículo científico publicado en 2012

ABC2 Consensus Conference on Advanced Breast Cancer: Brief Summary of the Consensus Panel on Saturday November 9, 2013

artículo científico publicado en 2013

ABC3 Consensus: Assessment by a German Group of Experts

artículo científico publicado en 2016

AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013

artículo científico publicado en 2013

AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013.

artículo científico publicado en 2013

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 ⬇️

artículo científico publicado el 1 de agosto de 2012

AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011 ⬇️

artículo científico publicado el 30 de agosto de 2011

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

scientific article published on 20 September 2020

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

artículo científico publicado en 2015

Advanced statistical methods for the definition of new staging models

artículo científico publicado en 2003

Afatinib in the treatment of breast cancer

artículo científico publicado en 2014

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

artículo científico publicado en 2016

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

artículo científico publicado en 2021

Angiogenesis inhibitors in the management of breast cancer

scientific article published on February 2010

Antibody therapy for breast cancer

artículo científico publicado en 2005

Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance

artículo científico publicado en 2019

Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects ⬇️

artículo científico publicado el 15 de octubre de 2008

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

artículo científico publicado en 2018

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer

scientific article published on 16 September 2019

Breast Cancer Is Our Global Responsibility

artículo científico publicado en 2015

CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients

artículo científico publicado en 2010

Can We Keep the 'PROMISE'? AGO Breast Commission: Commentary on Recent Evidence Regarding LHRH Analogues for the Preservation of Ovarian Function

artículo científico publicado en 2011

Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 ⬇️

artículo científico publicado el 1 de julio de 2011

Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer ⬇️

artículo científico publicado el 14 de marzo de 2012

Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

artículo científico publicado en 2010

Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer ⬇️

artículo científico publicado el 24 de abril de 2008

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer

artículo científico publicado en 2008

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

artículo científico publicado en 2008

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

artículo científico publicado en 2020

Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

artículo científico publicado en 2010

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts

artículo científico publicado en 2002

Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update

artículo científico publicado en 2006

Cutting-edge therapy concepts - cure metastatic breast cancer?

artículo científico publicado en 2014

DNA methylation as a biomarker in breast cancer

artículo científico publicado en 2009

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and T

artículo científico publicado en 2017

Detection and clinical implications of early systemic tumor cell dissemination in breast cancer.

artículo científico publicado en 2003

Detection of micrometastatic disease in bone marrow: is it ready for prime time?

artículo científico publicado en 2005

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

artículo científico publicado en 2010

EHealth Acceptance and New Media Preferences for Therapy Assistance Among Breast Cancer Patients

artículo científico publicado en 2016

Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic

scientific article published on 08 June 2020

Facilitating Early Integration of Palliative Care into Breast Cancer Therapy. Promoting Disease-Specific Guidelines ⬇️

artículo científico publicado el 3 de junio de 2011

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study

artículo científico publicado en 2016

Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature ⬇️

artículo científico publicado el 16 de diciembre de 2011

Filariasis of the axilla in a patient returning from travel abroad: a case report

scientific article published on December 2012

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

scientific article published on 12 December 2019

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

artículo científico publicado en 2010

Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients

artículo científico publicado en 2017

From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cance

artículo científico publicado en 2014

G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients

artículo científico publicado en 2006

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer

artículo científico publicado en 2013

German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer ⬇️

artículo científico publicado el 13 de marzo de 2013

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

artículo científico publicado en 2013

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

artículo científico publicado en 2020

Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients

artículo científico publicado en 2004

Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research

artículo científico publicado en 2004

Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy – a Pilot Project ⬇️

artículo científico publicado el 14 de junio de 2011

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

artículo científico publicado en 2010

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer

artículo científico publicado en 2009

Is routine audiometric evaluation necessary in gynaecologic tumour patients undergoing chemotherapy?

artículo científico publicado en 2013

Lobular breast cancer: Clinical, molecular and morphological characteristics

artículo científico publicado en 2016

Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.

artículo científico publicado en 2003

Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setti

artículo científico publicado en 2022

Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow

artículo científico

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

artículo científico publicado en 2006

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

artículo científico publicado en 2008

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?

artículo científico publicado en 2018

OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery

artículo científico publicado en 2014

Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations

artículo científico

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

artículo científico publicado en 2015

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs

artículo científico publicado en 2014

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

artículo científico publicado en 2015

Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early

artículo científico publicado en 2013

Personalized treatment of early-stage breast cancer: present concepts and future directions

artículo científico publicado en 2010

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

artículo científico publicado en 2015

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

artículo científico publicado en 2010

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

artículo científico publicado en 2010

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

artículo científico publicado en 2014

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer ⬇️

artículo científico publicado el 1 de enero de 2010

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel

artículo científico publicado en 2011

Recommendations for collection and handling of specimens from group breast cancer clinical trials

artículo científico publicado en 2008

Recover your smile: Effects of a beauty care intervention on depressive symptoms, quality of life, and self-esteem in patients with early breast cancer

artículo científico publicado en 2018

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

artículo científico publicado en 2015

Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective

artículo científico publicado en 2014

Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer

artículo científico publicado en 2013

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.

artículo científico publicado en 2014

St. Gallen 2011: Summary of the Consensus Discussion

artículo científico publicado en 2011

St. Gallen 2013: brief preliminary summary of the consensus discussion

artículo científico publicado en 2013

St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion

artículo científico publicado en 2015

Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene ⬇️

artículo científico publicado el 26 de abril de 2010

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.

artículo científico publicado en 2008

The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer ⬇️

artículo científico publicado el 29 de octubre de 2012

The Future of Breast Cancer Management

artículo científico publicado en 2008

The oncological emergency case: paraneoplastic hypoglycemia in metastatic breast cancer - case report and brief review of the literature

artículo científico publicado en 2013

The patient experience

artículo científico publicado en 2007

The role of capecitabine in first-line treatment for patients with metastatic breast cancer

artículo científico publicado en 2006

Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis

artículo científico publicado en 2014

Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching

artículo científico publicado en 2007

Truly personalized therapy - an end to the era of one size fits all

scientific article published on 01 February 2019

Tumor markers: from laboratory to clinical utility

artículo científico publicado en 2003

Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms

artículo científico publicado en 2007

Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer – Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer ⬇️

artículo científico publicado el 27 de octubre de 2010

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer

artículo científico publicado en 2004

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investiga

artículo científico publicado el 19 de agosto de 2013

Web-/APP-based connected care solution for COVID-19 in- and outpatient care

artículo científico publicado en 2020

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

artículo científico publicado en 2016

Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).

artículo científico publicado en 2009

eHealth in Modern Patient-Caregiver Communication: High Rate of Acceptance Among Physicians for Additional Support of Breast Cancer Patients During Long-Term Therapy.

artículo científico publicado en 2016

uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda